Influenza vaccination and hospitalizations among COVID-19 infected adults

Ming-Jim Yang, MD, MS¹; Benjamin J. Rooks, MS¹; Thanh-Tam Thi Le, MD¹; Inocente O. Santiago III, MD¹; Jeffrey Diamond, BS¹; Nicholas L. Dorsey, MD¹; Arch G. Mainous III, PhD¹²

1 Department of Community Health and Family Medicine, College of Medicine, University of Florida

2 Department of Health Services Research, Management and Policy, University of Florida

Corresponding author:
Ming-Jim Yang, MD
Department of Community Health and Family Medicine
University of Florida
PO Box 100237
Gainesville, FL 32610-0237
Tel: 352-273-5159
Fax: 352-273-5213
mjyang527@ufl.edu

Disclosures: All authors report nothing to disclose and no conflicts of interest.

Acknowledgements:

We acknowledge the University of Florida Integrated Data Repository (IDR) and the UF Health Office of the Chief Data Officer for providing the analytic data set for this project. Additionally, the Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under University of Florida Clinical and Translational Science Awards UL1TR000064 and UL1TR001427.

The content of this publication, presentation and/or proposal is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Word count: 1196
Abstract

*Introduction*: To date, there are no effective treatments for decreasing hospitalizations in COVID-19 infections. It has been suggested that the influenza vaccine might attenuate the severity of COVID-19.

*Methods*: This is a retrospective single-centered cohort review of a de-identified database of 2,005 patients over the age of 18 within the University of Florida health care system who tested positive for COVID-19. Comorbidities and influenza vaccination status were examined. Primary outcome was severity of disease as reflected by hospitalization and ICU admission. A logistic regression was performed to examine the relationship between influenza status and hospitalization.

*Results*: Covid-19 positive patients who had not received the influenza vaccination within the last year had a 2.44 (1.68, 3.61) greater odds of hospitalization and a 3.29 (1.18, 13.77) greater odds of ICU admission when compared to those who were vaccinated. These results were controlled to account for age, race, gender, hypertension, diabetes, COPD, obesity, coronary artery disease, and congestive heart failure.
Discussion: Our analysis suggests that the influenza vaccination is potentially protective from moderate and severe cases of COVID-19 infection. This protective effect holds regardless of comorbidity. The literature points to a potential mechanism via natural killer cell activation. Though our data potentially is limited by its generalizability and our vaccination rate is low, it holds significant relevance given the upcoming influenza season. Not only could simply encouraging influenza vaccination decrease morbidity and mortality from the flu, but it might help flatten the curve in regards to the COVID-19 epidemic as well. We encourage further studies into this finding.
Introduction

By September, 2020, Coronavirus disease 2019 (COVID-19) has resulted in over 200,000 deaths in the United States and 950,000 worldwide.\textsuperscript{1} Although risk factors like older age and comorbid disease are associated with severe outcomes, no effective treatments to decrease the likelihood of hospitalizations in COVID-19 infections have been identified.\textsuperscript{2} It has been suggested that influenza vaccination may attenuate the impact of COVID-19 potentially through a vaccine-induced change in innate immunity.\textsuperscript{3} While the influenza vaccination specifically offers protection against influenza, there is some discussion that, natural influenza infection may reduce the risk of non-influenza respiratory viruses by providing a non-specific immunity against these viruses in a cross-reactivity strategy.\textsuperscript{4,5} Conversely, some authors have suggested that influenza vaccination may create a virus interference where vaccinated individuals may be at increased risk for other respiratory viruses because they do not receive the non-specific immunity associated with natural infection.\textsuperscript{6-8} The data on influenza vaccination interference is mixed.\textsuperscript{8} The objective of this project was to investigate if being up to date on influenza vaccinations is associated with a less severe response to COVID-19 infection as indicated by hospitalizations.

Methods

Data for this project was obtained from a research databank containing de-identified information from the electronic health records (EHR) of patients tested for COVID-19 in
the University of Florida Health system. Usage of the databank for research is not considered human subjects research and IRB review was not required to conduct this study. The cohort for this study consisted of all adult patients (18 and older) with a confirmed diagnosis of COVID-19, between the dates of Mar and August, who established care at UF Health at least one year before their earliest confirmed diagnosis of COVID-19. The presence of a positive laboratory test for COVID-19 in the EHR was used to confirm COVID-19 diagnoses. Each patient’s influenza vaccination status was determined using CPT codes located in the EHR. Patients were considered up-to-date on their influenza vaccination if their EHR indicated administration of the vaccine within one year of their earliest confirmed diagnosis of COVID-19. Additionally, hospital encounters and ICU stays associated with a confirmed diagnosis of COVID-19 were recorded for all patients in the cohort. Comorbidities which were found to be prevalent among hospitalized COVID-19 patients were recorded as well. In total, 2,005 COVID-19 patients were included into our cohort.

Unadjusted logistic regression models were used to compare the odds of COVID-19-related hospitalization or intensive care (ICU) hospitalization between patients with an up-to-date influenza vaccination and those without. Logistic regression analyses were subsequently adjusted for the potential confounders of gender, race/ethnicity, age, hypertension, diabetes, COPD, obesity, coronary artery disease, and heart failure in a forced inclusion model. All analyses were conducted in R 3.6.3.
Results

Table 1 includes baseline characteristics of the cohort. Of the 2005 patients included in our cohort, 214 (10.7%) patients were considered up-to-date on the influenza vaccine. This subpopulation of our cohort was found to have less males but had no difference in ethnic breakdown. The vaccinated group overall also had less comorbidities.

Hospitalization and ICU admission were used as surrogate markers for moderate and severe COVID-19 disease. Our analysis indicates that individuals, who had not received the influenza vaccination in the last year, who tested positive for COVID-19 had 2.84 (95% CI 2.03 - 4.07) higher odds of being hospitalized when compared to patients who were vaccinated (Table 2). Similarly, the unadjusted odds of ICU admission in unvaccinated, COVID-19 positive individuals was 5.64 (95% CI 2.11 - 23.01) when compared to vaccinated COVID-19 patients. This treatment effect was maintained for both hospital admission and ICU admission when adjusted for age, ethnicity, and medical comorbidities (Table 2).

Discussion

Our data strongly suggests that COVID-19 positive patients who are not up-to-date on the influenza vaccination have higher odds of hospitalization. A review of both peer reviewed and non peer-reviewed literature on the association between influenza
vaccination and influenza associated COVID-19 morbidity and mortality found no evidence that would suggest clinical manifestations in COVID-19 patients with influenza co-infection differ from those without co-infection.\textsuperscript{9} Thus, our results, which are not focused on influenza co-infection, are the first to point to a potential protective effect of influenza vaccination for hospitalization in individuals with COVID-19.

The implications of these findings are substantial, particularly for family medicine. With limited strategies available to effectively decrease the severity of outcomes among COVID-19 patients, influenza vaccination has several attractive qualities. Influenza vaccination is inexpensive, non-invasive, and well accepted in the population. Further, the mechanisms for distribution in the population are well established. The role of the family physician in prevention of COVID-19 outcomes with this strategy is particularly important.

It is possible to speculate that the individuals who get flu shots are healthier because of a healthier lifestyle. Everyone in the study was COVID-19 positive so a healthier lifestyle and fewer comorbidities may correlate with influenza vaccines and less severe outcomes. However, the adjusted analyses controlled for the relevant comorbidities related to COVID severity and the effect was still quite strong. That said, we controlled only for comorbidities previously shown to be related to COVID severity. There may be
other variables that we are unaware of that may play a role in obtaining influenza vaccines and COVID severity that could be worthy of future investigations.

There are several limitations to our study. This study is a single-centered study, which makes its generalizability to the national population unclear. Additionally, although influenza vaccination status was recorded in the EHR, this is not the gold standard for assessing vaccination coverage. There may be some misclassification of vaccinated individuals into the unvaccinated group. However, since that would likely dilute our treatment effect, the strength of the association is then particularly striking.

As stated previously, there is no clear mechanism by which the influenza vaccination might be protecting against COVID-19 infection severity. As discussed above, there is some evidence of cross-reactivity of antibodies from low-pathogenic coronavirus with COVID-19, but there is no evidence of cross-reactivity of the influenza induced antibodies with the SARS-COV2. A literature search provides two theories that might explain our results. The first is that an adjuvant within the flu vaccine is triggering a heightened immune response which may provide protective effects against COVID-19. We know that certain influenza vaccinations contain MF59, an oil-in-water emulsion of squalene, which has been used to potentiate the immunogenicity of the influenza vaccine. MF59 has been studied in SARS-COV vaccines and shown to be helpful in stimulating an immune response. Another intriguing theory is that the influenza
vaccine could be affecting NK (natural killer cell) cytotoxicity levels. Though the exact role of NK cells in fighting a viral infection is still unclear, there have been increasing studies showing some role of NK cells in fighting virally-infected cells. SARS-CoV-2 has been shown to dramatically lower NK cell activity in moderate to severe diseased patients.\textsuperscript{13} Influenza vaccination and infection have been shown to increase NK cell activity.\textsuperscript{12} Patients who have been vaccinated may have a more “primed” pool of NK cells and thus be able to suppress a COVID-19 infection more efficiently.

We believe that these preliminary findings are significant but require further study. When considering its widespread availability and safety profile, it is an intriguing prospect that influenza vaccination may be an effective protection against COVID-19 morbidity.
Table 1. Baseline characteristics of the cohort

|                                      | Up-To-Date Vaccination-18+ | No Up-To-Date Vaccination-18+ |
|--------------------------------------|----------------------------|-------------------------------|
| N                                    | 214 (10.7%)                | 1,791 (89.3%)                 |
| Hospitalization for COVID-19         | 43 (20.1%)                 | 747 (41.7%)                   |
| ICU Admission for COVID-19           | 3 (1.4%)                   | 133 (7.4%)                    |
| Age (mean/SD)                        | 40.7 (16.3)                | 46.5 (19.1)                   |
| Gender                               |                            |                               |
| Male                                 | 65 (30.7%)                 | 733 (40.9%)                   |
| Female                               | 149 (69.3%)                | 1,058 (59.1%)                 |
| Race/Ethnicity                       |                            |                               |
| Non-Hispanic White                   | 97 (45.3%)                 | 713 (40.4%)                   |
| Non-Hispanic Black                   | 73 (34.1%)                 | 772 (43.8%)                   |
| Hispanic                             | 24 (11.3%)                 | 170 (9.6%)                    |
| Other Race/Ethnicity                 | 20 (9.3%)                  | 108 (6.2%)                    |
| Hypertension                         | 22 (10.3%)                 | 385 (21.5%)                   |
| Diabetes                             | 19 (8.9%)                  | 232 (13.0%)                   |
| COPD                                 | 3 (1.4%)                   | 78 (4.4%)                     |
| Obesity                              | 14 (6.5%)                  | 192 (10.7%)                   |
| Coronary Artery Disease              | 2 (0.9%)                   | 103 (5.8%)                    |
| Congestive Heart Failure             | 2 (0.9%)                   | 102 (5.7%)                    |
Table 2. Odds ratios for COVID-19 related hospitalizations between confirmed adult COVID-19 patients without up-to-date influenza vaccination versus those who were up-to-date

|                          | Crude OR (95% CI) | Adjusted OR* (95% CI) |
|--------------------------|-------------------|-----------------------|
| Hospitalization          | 2.84 (2.03, 4.07) | 2.44 (1.68, 3.61)     |
| ICU Admission            | 5.64 (2.11, 23.01)| 3.29 (1.18, 13.77)    |

*Model adjusted for race, age, gender, hypertension, diabetes, COPD, obesity, coronary artery disease, and congestive heart failure
REFERENCES

1. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). https://coronavirus.jhu.edu/map.html. Accessed Sept 19, 2020.

2. Garg S, Kim L, Whitaker M, et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020. MMWR Morb Mortal Wkly Rep. Apr 2020;69(15):458-464.

3. Sultana J, Mazzaglia G, Luxi N, et al. Potential effects of vaccinations on the prevention of COVID-19: rationale, clinical evidence, risks, and public health considerations. Expert Rev Vaccines. Oct 2020;1-18.

4. Ma Z, Li P, Ikram A, Pan Q. Does Cross-neutralization of SARS-CoV-2 Only Relate to High Pathogenic Coronaviruses? Trends Immunol. 10 2020;41(10):851-853.

5. Jiang S, Du L. Effect of Low-Pathogenic Human Coronavirus-Specific Antibodies on SARS-CoV-2. Trends Immunol. 10 2020;41(10):853-854.

6. Cowling BJ, Fang VJ, Nishiura H, et al. Increased risk of noninfluenza respiratory virus infections associated with receipt of inactivated influenza vaccine. Clin Infect Dis. Jun 2012;54(12):1778-1783.

7. Suzuki M, Camacho A, Ariyoshi K. Potential effect of virus interference on influenza vaccine effectiveness estimates in test-negative designs. Epidemiol Infect. Dec 2014;142(12):2642-2646.

8. Wolff GG. Influenza vaccination and respiratory virus interference among Department of Defense personnel during the 2017-2018 influenza season. Vaccine. 01 2020;38(2):350-354.

9. Thindwa D, Garcia Quesada M, Liu Y, et al. Use of seasonal influenza and pneumococcal polysaccharide vaccines in older adults to reduce COVID-19 mortality. Vaccine. 07 2020;38(34):5398-5401.

10. HEDIS Measures for Flu and vaccinations. National Committee on Quality Assurance, 2020. https://www.ncqa.org/hedis/measures/flu-vaccinations/. Accessed Sept 19, 2020.

11. Gupta T, Gupta SK. Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses. Int Immunopharmacol. Sep 2020;86:106717.

12. Jost S, Altfeld M. Control of human viral infections by natural killer cells. Annu Rev Immunol. 2013;31:163-194.

13. Jewett A. The Potential Effect of Novel Coronavirus SARS-CoV-2 on NK Cells; A Perspective on Potential Therapeutic Interventions. Front Immunol. 2020 2020;11:1692.